Stimulant vs nonstimulant ADHD medication for adults

"Stimulant or nonstimulant?" is usually the first fork in an adult ADHD medication conversation. The two groups differ in how strong the evidence is, in their warnings, and in how the law treats them, which affects refills and follow-up in New York and New Jersey. This article sets out those differences using FDA labels and published guidelines. It does not recommend any medication for any reader.

Who is in each group

• Stimulants: the amphetamine family (mixed amphetamine salts, lisdexamfetamine, dextroamphetamine) and the methylphenidate family (methylphenidate, dexmethylphenidate, and serdexmethylphenidate combined with dexmethylphenidate).
• Nonstimulants approved for adults: atomoxetine (generic capsules; brand Strattera is listed as discontinued in the October 2026 Orange Book) and viloxazine (Qelbree). Both labels state an indication for ADHD in adults and pediatric patients 6 and older.
• Nonstimulants used off-label in adults: guanfacine extended-release (Intuniv), whose label studies were in children and adolescents, and bupropion, which is not FDA-approved for ADHD.

One newer product does not fit the old labels neatly. Centanafadine (Simtriyo), approved by the FDA on July 24, 2026, is described by its manufacturer as a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant, with a boxed warning on abuse, misuse and addiction. As of October 19, 2026, no DEA scheduling action for it had appeared in the Federal Register, and the manufacturer said it expects availability after scheduling.

Side by side

What the evidence says

In the 2018 network meta-analysis by Cortese and colleagues, which pooled 133 double-blind trials, adult effect sizes versus placebo on clinician ratings at about 12 weeks were -0.79 for amphetamines, -0.49 for methylphenidate and -0.45 for atomoxetine. Viloxazine's adult approval came after that analysis. The authors concluded that amphetamines were a preferred first choice for short-term treatment in adults. Amphetamines, methylphenidate and atomoxetine all led to more dropouts for side effects than placebo.

The 2025 analysis by Ostinelli and colleagues (113 trials, 14,887 adults) found stimulants and atomoxetine were the only interventions that reduced core symptoms on both self-rated and clinician-rated scales. Atomoxetine was less acceptable than placebo, meaning more people stopped it for any reason. The same paper found that guanfacine had lower acceptability than placebo. How to read these numbers is explained in how ADHD medications work.

When guidelines point to a nonstimulant

The United States had no published adult ADHD guideline as of October 19, 2026. APSARD's guidelines page announced a final review stage in August 2026 but listed no published document. Clinicians therefore lean on England's NICE guideline, a graded US clinical review and FDA labels. Clinical guidelines for adult ADHD compares them.

• NICE NG87 recommends offering lisdexamfetamine or methylphenidate as first-line medication for adults. It recommends atomoxetine if the person cannot tolerate lisdexamfetamine or methylphenidate, or if symptoms have not responded to separate 6-week trials of each. It advises against guanfacine for adults without advice from a tertiary ADHD service and notes that this use is off-label.
• American Family Physician (2024) rates stimulants as first-line drug therapy and says nonstimulants such as atomoxetine, viloxazine and bupropion are indicated when stimulants are contraindicated, not tolerated or ineffective. It lists them among options for adults who cannot take stimulants or who have concurrent anxiety or depression.
• Misuse and diversion: NICE advises caution with stimulants where there is a risk of diversion and says not to offer immediate-release stimulants, or modified-release ones that can be easily injected or snorted, if there is a risk of misuse. The American Family Physician review suggests controlled substance agreements and prescription monitoring programs.

One common belief is not supported by NICE: that anxiety or tics automatically rule out a stimulant. The guideline says to offer the same medication choices to people with ADHD and an anxiety disorder, tic disorder or autism spectrum disorder as to other people with ADHD. Labels still call for attention to these conditions, and a prescriber weighs them individually.

Warnings that differ between the groups

• Stimulants: the boxed warning says they have a high potential for abuse and misuse, which can lead to a substance use disorder, including addiction. Labels advise avoiding use in people with serious heart disease, monitoring blood pressure and pulse, and screening for risk factors for mania before starting.
• Atomoxetine: the label's contraindications include narrow angle glaucoma, pheochromocytoma and severe heart or blood vessel disorders. It warns of severe liver injury and asks prescribers to screen for bipolar disorder risk factors.
• Viloxazine: it is contraindicated with MAOIs and with sensitive CYP1A2 substrates or those with a narrow therapeutic range, because viloxazine is a strong CYP1A2 inhibitor and significantly increases their total exposure. Bring a full medication list to any appointment.
• Both groups: use with an MAOI, or within 14 days of stopping one, is contraindicated.

Side effects are covered in more depth in ADHD medication side effects in adults.

The legal difference in New York and New Jersey

Because stimulants are Schedule II, federal law bars refills, and both states limit a single prescription to a 30-day supply with routes to a longer supply. New York allows up to a three-month supply for attention deficit disorder when the prescription states the condition or its code. New Jersey allows multiple prescriptions totaling up to 90 days, each with an earliest fill date. New Jersey also requires an in-person visit within 30 days for adult Schedule II stimulant patients located in New Jersey who start by telehealth, and at least one in-person visit a year. None of these stimulant-specific rules applies to atomoxetine or viloxazine.

Details are in New York's rules for ADHD stimulant prescriptions, New Jersey's ADHD medication rules and ADHD medication schedules explained.

Questions worth asking

• Is there a reason a stimulant would or would not suit me, given my heart health, history and other medications?
• If we try a nonstimulant, how long before we judge whether it is working?
• What happens if the first choice does not work or I cannot tolerate it?
• How will follow-up and prescriptions work where I will be located for visits?

Dr. Shershow, a psychiatrist licensed in New York and New Jersey, discusses these trade-offs as part of treatment planning after an adult ADHD evaluation. A broader look at how prescribers weigh the options is in how doctors choose an ADHD medication.